Wenzhou Medical University.
Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University.
Am J Clin Oncol. 2023 May 1;46(5):193-198. doi: 10.1097/COC.0000000000000980. Epub 2023 Mar 30.
Investigate the survival of patients with stage III colorectal cancer (CRC) treated with immediate postoperative intraperitoneal chemotherapy.
The clinical data of 195 patients with stage III CRC admitted to The First Affiliated Hospital of Wenzhou Medical University from June 2017 to June 2018 were retrospectively analyzed. The patients were divided into an observation group and a control group, both groups were treated with the routine laparoscopic radical operation, on the basis of which, the patients in the observation group were treated with intraperitoneal perfusion chemotherapy during the operation. The local recurrence, abdominal cavity metastasis, and liver metastasis were followed up, and the time of disease recurrence and total survival were recorded.
The survival analysis showed that there was a significant difference in progression-free survival (χ 2 = 5.416, P = 0.020) and overall survival (χ 2 = 4.673, P = 0.031) between the observation group and the control group.
During laparoscopic radical resection of CRC, the use of intraperitoneal chemotherapy with raltitrexed can achieve satisfactory results and improve the survival rate of patients with stage III CRC, perioperative use of raltitrexed has been shown to be beneficial in terms of overall survival and progression-free survival.
探讨术后即刻腹腔内化疗治疗 III 期结直肠癌(CRC)患者的生存情况。
回顾性分析 2017 年 6 月至 2018 年 6 月温州医科大学附属第一医院收治的 195 例 III 期 CRC 患者的临床资料。患者分为观察组和对照组,两组均行常规腹腔镜根治术,观察组患者术中行腹腔灌注化疗。随访局部复发、腹腔转移和肝转移情况,记录疾病复发时间和总生存时间。
生存分析显示,观察组与对照组患者无进展生存期(χ 2 = 5.416,P = 0.020)和总生存期(χ 2 = 4.673,P = 0.031)差异有统计学意义。
在 CRC 腹腔镜根治性切除术中,应用雷替曲塞腹腔化疗可获得满意效果,提高 III 期 CRC 患者的生存率,围手术期应用雷替曲塞在总生存期和无进展生存期方面均显示出获益。